Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
Cochrane Database of Systematic ReviewsPublished 24 July 2000
Helle Krogh Johansen, Peter C Gøtzsche
Citations43
SJR quartileQ1
SJR score1.62
SNIP2.04
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
AmBisome is a better drug than conventional amphotericin B but its high cost prohibits routine use in most settings, and the advantages of AmBISome may be smaller than indicated in the review if conventional amph esotericin B is administered under optimal circumstances.
Abstract
AmBisome is a better drug than conventional amphotericin B but its high cost prohibits routine use in most settings. Furthermore, the advantages of AmBisome may be smaller than indicated in our review if conventional amphotericin B is administered under optimal circumstances. It is not clear whether other lipid formulations of amphotericin B could offer a worthwhile advantage compared to conventional amphotericin B.
Keywords
Medicine
New England Journal of MedicineLiposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
1,195 Citations1999Thomas J. Walsh, Robert W. Finberg +11 more
Liposomal amphotericin B is as effective as conventional amphoteric in B for empirical antifungal therapy in patients with fever and neutropenia, and it is associated with fewer breakthrough fungal infections, less infusion-related toxicity, and less nephrotoxicity.
Clinical Infectious DiseasesLiposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
731 Citations2007Oliver A. Cornely, Johan Maertens +18 more
In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%.
Clinical Infectious Diseases1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
672 Citations1997Walter T. Hughes, Donald Armstrong +8 more
This is the first in a series of practice guidelines commissioned by the Infectious Diseases Society of America through its Practice Guidelines Committee to provide assistance to clinicians when making decisions on treating the conditions specified in each guideline.
British Journal of HaematologyA randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
438 Citations1997H. G. Prentice, Ian Hann +11 more
In both the paediatric and adult populations, L‐AMB treated patients had a 2–6‐fold decrease in the incidence of test‐drug‐related side‐effects, compared to c‐ AMB.
Clinical Infectious DiseasesInternational Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections
426 Citations1997John E. Edwards, Gerald P. Bodey +20 more
Because of the rapidly increasing incidence of serious candidal infections, a consensus conference of 22 investigators from the United States, Europe, and Japan was held to discuss strategies for the prevention and treatment of deep-organ infections caused by Candida species.
Clinical Infectious DiseasesA Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients
327 Citations2002Raleigh A. Bowden, Pranatharthi Chandrasekar +8 more
ABCD appears to have equivalent efficacy and superior renal safety, compared with AmB, in the treatment of invasive aspergillosis, however, infusion-related chills and fever occurred more frequently in patients receiving ABCD than in those receiving AmB.
British Journal of HaematologyLiposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections
321 Citations1998Alexander C. A. P. Leenders, Simon Daenen +10 more
A randomized multicentre study comparing liposomal amphotericin B (AmBisome, 5 mg/kg/d) to amphoteric in B deoxycholate (Am b) in the treatment of neutropenia‐associated invasive fungal infections, finding a favourable trend at day 14 and lower mortality rates in patients with documented infections.
Clinical Infectious DiseasesRandomized, Double‐Blind Clinical Trial of Amphotericin B Colloidal Dispersion vs. Amphotericin B in the Empirical Treatment of Fever and Neutropenia
303 Citations1998Mary H. White, Raleigh A. Bowden +10 more
ABCD appeared comparable in efficacy with amphotericin B, and renal dysfunction associated with ABCD was significantly less than that associated with amphonicin B; however, infusion-related events were more common with ABCd treatment than with amph esotericin B treatment.
Clinical Infectious DiseasesAn EORTC International Multicenter Randomized Trial (EORTC Number 19923) Comparing Two Dosages of Liposomal Amphotericin B for Treatment of Invasive Aspergillosis
254 Citations1998Michael Ellis, David J. Spence +13 more
This is the first completed prospective randomized clinical efficacy trial of antifungals in the treatment of invasive aspergillosis (IA) and the first to compare the clinical efficacy of two dosages of liposomal amphotericin B (L-AmB) for IA in neutropenic patients with cancer or those undergoing bone marrow transplantation.
BMJComparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial
234 Citations2001Urs Eriksson, Burkhard Seifert +1 more
Testing the hypothesis that amphotericin B deoxycholate is less toxic when given by continuous infusion than by conventional rapid infusion found it to reduce nephrotoxicity and side effects related to infusion without increasing mortality.
Journal of Clinical OncologyPharmacoeconomic Analysis of Liposomal Amphotericin B Versus Conventional Amphotericin B in the Empirical Treatment of Persistently Febrile Neutropenic Patients
153 Citations2000Pablo J. Cagnoni, Thomas J. Walsh +9 more
The cost of liposomal amphotericin B and patient risk for developing nephrotoxicity play large roles in determining whether liposome amphoteric in B is cost-effective as first-line empirical therapy in persistently febrile neutropenic patients.
Journal of the American Statistical AssociationAn Assessment of Publication Bias Using a Sample of Published Clinical Trials
127 Citations1989Jesse A. Berlin, Colin B. Begg +1 more
There are striking trends for each endpoint, with small studies appearing to possess large treatment effects and large studies possessing relatively small effects, and it is believed that these differences are primarily due to publication bias.
Journal of Antimicrobial ChemotherapyReduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neotropenic patients
120 Citations1992Philippe Moreau, Nöel Milpied +3 more
Preparation of amphotericin B with Intralipid reduces nephrotoxicity, improves clinical tolerance, may allow an increase in the daily dose of amph esotericin B, and be an alternative to liposomal-amphotericin B infusion.
Clinical Infectious DiseasesContinuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open‐Label Observational Study
117 Citations2003Alexander Imhof, Roland B. Walter +1 more
Continuous infusion of AmB-d escalated to 2.0 mg/kg/day seems not to cause additional impairment of vital organ functions and to be well tolerated by most patients.
BMJMeta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
107 Citations1997P. C Gotzsche, H. Johansen
European Journal Of HaematologyLow‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial
85 Citations2004Maricel Subirá, Rodrigo Martino +4 more
Conventional amphotericin B lipid complex (ABLC) has been investigated for this indication due to its low toxicity profile, and the recommended dose of ABLC is five to seven times higher than the recommended doses of c‐AmB.
Journal of Antimicrobial ChemotherapyLiposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
85 Citations2002Pablo J. Cagnoni
The drug acquisition costs and the risk of nephrotoxicity are important factors in determining the cost-effectiveness of liposomal amphotericin B as empirical therapy in persistently febrile neutropenic patients.
The American journal of pediatric hematology/oncologyUse of Amphotericin B Colloidal Dispersion in Children
76 Citations2000Eric Sandler, Mahmoud M. Mustafa +9 more
ABCD was well-tolerated at doses up to 5 times greater then those usually tolerated with amphotericin B, and Renal toxicity was markedly less than expected, and there were no other unexpected severe toxicities.
Antimicrobial Agents and ChemotherapyDouble-blind randomized study of the effect of infusion rates on toxicity of amphotericin B
75 Citations1992Michael Ellis, Abdullah Alhokail +6 more
A rapid infusion regimen for amphotericin B cannot be recommended, at least during the first 5 to 7 days of treatment, and by day 7 the incidence and severity were the same.
BMJSafety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study
73 Citations1998Patrick Schöffski, Mathias Freund +6 more
Amphotericin B 0.75 mg/kg/day in intralipid given on eight consecutive days then alternate days provides no benefit and is associated with potential pulmonary side effects possibly because of fat overload or an incompatibility of the two drugs.
Journal of Antimicrobial ChemotherapyA controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies
63 Citations1994Denis Caillot, Guillaume Reny +8 more
Patients with haematological malignancies requiring an antifungal therapy were randomly assigned to receive amphotericin B diluted in either 5% dextrose or in fat emulsion (Intralipid).
Antimicrobial Agents and ChemotherapyComparison of the Toxicity of Amphotericin B in 5% Dextrose with That of Amphotericin B in Fat Emulsion in a Randomized Trial with Cancer Patients
61 Citations1999Márcio Nucci, Monique Morgado Loureiro +6 more
Amphotericin B diluted in a lipid emulsion seems to be associated with a smaller number of acute adverse events and fewer cases of hypokalemia than amphotericinB diluted in 5% dextrose.
Antimicrobial Agents and ChemotherapyAmphotericin B in Children with Malignant Disease: a Comparison of the Toxicities and Pharmacokinetics of Amphotericin B Administered in Dextrose versus Lipid Emulsion
58 Citations1999Christa E. Nath, Peter J. Shaw +3 more
It was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infusion in lipid emulsion, with there being no difference between the two methods of AmB administration.
Cochrane Database of Systematic ReviewsRoutine versus selective antifungal administration for control of fungal infections in patients with cancer
51 Citations2002Peter C Gøtzsche, Helle Krogh Johansen
Routine prophylactic or later therapy with antifungal drugs in cancer patients with neutropenia does not appear to have a beneficial effect on mortality and only a modest effect on fungal invasion.
Cochrane Database of Systematic ReviewsAmphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
43 Citations2000Helle Krogh Johansen, Peter C Gøtzsche
AmBisome is a better drug than conventional amphotericin B but its high cost prohibits routine use in most settings, and the advantages of AmBISome may be smaller than indicated in the review if conventional amph esotericin B is administered under optimal circumstances.
Pediatric Hematology and OncologyConventional vs. Liposomal Amphotericin B in Immunosuppressed Children
34 Citations1992A. Zoubek, Wolfgang Emminger +5 more
Eleven immunosuppressed children who were treated with conventional or liposomal AMB for longer than 3 weeks and showed signs of improvement in the treatment of systemic fungal infections are reported on.
MycosesLiposomal amphotericin B for prophylaxis of invasive fungal infections in high‐risk paediatric patients with chemotherapy‐related neutropenia: interim analysis of a prospective study
31 Citations2001S. Uhlenbrock, Martina Zimmermann +3 more
A retrospective analysis of children with cancer at high risk for IFI treated at Mu¨nster University Hospital showed that the incidence and lethality of documented IFI were lower in patients receiving systemic antifungal prophylaxis with liposomal amphotericin B (l‐AmB) in comparison to a historical control group.
Supportive Care in CancerMust we really fear toxicity of conventional amphotericin B in oncological patients?
27 Citations1999Jiří Mayer, Michael Doubek +1 more
Sufficient hydration of patients and ion supplementation corresponding to the amount lost by the kidneys is an effective prophylaxis for prevention of AmB-induced decrease in renal function and for countering imbalances of serum electrolyte concentrations during use of Amb.
Annals of PharmacotherapyAdministration of Lipid-Emulsion Versus Conventional Amphotericin B in Patients with Neutropenia
27 Citations1995Begoña Pascual, Ana Ayestarán +5 more
The clinical tolerance of lipid-emulsion infusions is similar to that of conventionally administered amphotericin B therapy, and Renal toxicity appears to be decreased when the drug is administered in a fat emulsion.
CancerAntifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia
24 Citations1991Wolfgang Hiddemann, M. Essink +4 more
The present data strongly suggest a myelosuppressive effect of ampho B/5‐FC antifungal treatment in patients after intensive chemotherapy for acute leukemias.
Journal of Internal MedicineAntifungal treatment in patients with cancer
18 Citations1997Claudio Viscoli, Elio Castagnola +1 more
Fluconazole may be indicated in high‐risk patients, although the duration of such prophylaxis should be limited as much as possible, in order to prevent selection of resistant strains and acquired resistance.
Clinical Microbiology and InfectionDo the new lipid formulations of amphotericin B really work?
10 Citations1997Christoph M. Tang, I.C.J.W. Bowler
It is suggested that local policies should be drawn up for the prescription of lipid formulations of amphotericin B and, until more compelling data are available, that these drugs only be administered after discussion with microbiologists or infectious diseases physicians.
BMC Medical Research MethodologyFungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents
6 Citations2006A.K. Due, Helle Krogh Johansen +1 more